NCT03526510进行中（未招募）不适用
Randomized Trial of Concomitant Hypofractionated IMRT Boost Versus Conventional Fractionated IMRT Boost for Localized High Risk Prostate Cancer
Dr. Patrick Cheung2 个研究点 分布在 1 个国家目标入组 178 人开始时间: 2011年6月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 178
- 试验地点
- 2
- 主要终点
- Acute Toxicity
研究概览
简要总结
Randomized trial comparing 2 external beam radiotherapy fractionation schemes in patients with localized high risk prostate cancer. Primary endpoint is acute toxicity.
详细描述
Patients enrolled onto this study will be randomized to one of the following treatment arms:
- Standard fractionation: Using 2 sequential IMRT plans, the pelvic lymph nodes and prostate will initially be treated to 46 Gy in 23 fractions, followed by a subsequent boost to the prostate to a total dose of 78 Gy.
- Hypofractionation: Using a one phase IMRT plan, the pelvic lymph nodes will be treated to a dose of 48 Gy in 25 fractions, while the prostate will be treated to a dose of 68 Gy in 25 fractions concomitantly (simulataneous integrated boost).
In addition, all patients receive 1.5- 3 years of androgen deprivation therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Written informed consent obtained.
- •Histologically confirmed diagnosis of adenocarcinoma of the prostate.
- •T1-2 N0 M0, Gleason Score <= 7, PSA 20 - 100
- •T1-2 N0 M0, Gleason Score 8 - 10, PSA <= 100
- •T3 N0 M0, any Gleason Score, PSA <= 100
排除标准
- •Patients with unilateral or bilateral hip replacement.
- •Patients with active collagen vascular disease.
- •Patients with active inflammatory bowel disease.
- •Patients with previous radiotherapy to the pelvis.
- •Patients with ataxia telangiectasia.
- •Patients with nodal or distant metastases
结局指标
主要结局
Acute Toxicity
时间窗: within 3 months after starting radiotherapy
Proportion of patients experiencing grade \>=2 acute toxicity
次要结局
- Biochemical Control (Phoenix Definition)(at 5 years)
- Overall Survival(at 5 years)
- Late Toxicity(beyond 3 months of starting radiotherapy)
研究者
Dr. Patrick Cheung
Radiation Oncologist
Sunnybrook Health Sciences Centre
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLCCarcinoma, Small CellLung NeoplasmsNCT02688036Cancer Institute and Hospital, Chinese Academy of Medical Sciences860
已完成
2 期
Trial of Hypofractionated Radiation Therapy for GlioblastomaGlioblastomaNCT02206230AHS Cancer Control Alberta133
已完成
3 期
Non Inferiority Trial of Standard RT Versus Hypofractionated Split Course in Elderly Vulnerable Patients With HNSCCHead and Neck Squamous Cell CarcinomaNCT01864850Groupe Oncologie Radiotherapie Tete et Cou202
进行中（未招募）
1 期
Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate CancerProstate AdenocarcinomaRadiation ToxicityNCT05003752German Oncology Center, Cyprus40
已完成
2 期
Very Intense Radiotherapy-chemotherapy Regimen in Advanced HNSCCOropharynx CancerHypopharynx CancerLarynx CancerOral CancerNCT00162708Gustave Roussy, Cancer Campus, Grand Paris120